Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 652 · Protecting Patients from Deceptive Drug Ads Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 333 Penalties

+24 −0Shown
More for 21 U.S.C. § 333
Read § 333Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 333) is amended by adding at the end the following:(h) (1) In the case of a social media influencer or health care provider who makes false or misleading communications regarding a drug approved under section 505 or licensed under section 351 of the Public Health Service Act, and subject to section 503(b), or compounded in …

§ 333(g)–(h)

Start of § 333 to (g)(7)(A) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(g)(7)(B)(B) (B)
after a court in an action brought under paragraph (6) has entered a final judgment in favor of the Secretary,after a court in an action brought under paragraph (6) has entered a final judgment in favor of the Secretary,
(g)(7)the Attorney General of the United States shall recover the amount assessed (plus interest at currently prevailing rates from the date of the expiration of the 60-day period referred to in paragraph (6) or the date of such final judgment, as the case may be) in an action brought in any appropriate district court of the United States. In such an action, the validity, amount, and appropriateness of such penalty shall not be subject to review.the Attorney General of the United States shall recover the amount assessed (plus interest at currently prevailing rates from the date of the expiration of the 60-day period referred to in paragraph (6) or the date of such final judgment, as the case may be) in an action brought in any appropriate district court of the United States. In such an action, the validity, amount, and appropriateness of such penalty shall not be subject to review.
(h)(h) [inserted: ]
(h)(1)(1) [inserted: ]
[inserted: In the case of a social media influencer or health care provider who makes false or misleading communications regarding a drug approved under section 505 or licensed under section 351 of the Public Health Service Act, and subject to section 503(b), or compounded in accordance with section 503A or 503B, shall be liable to the United States for a civil penalty in an amount described in paragraph (g)(1), in accordance with a process similar to the process described in paragraph (g)(2).]
(h)(2)(2) [inserted: ]
[inserted: For purposes of this paragraph—]
(h)(2)(A)(A) [inserted: ]
[inserted: the term “false or misleading communications”—]
(h)(2)(A)(i)(i) [inserted: ]
[inserted: means advertisements or promotional communications on a social media platform from which there is a financial benefit to the person engaging in such communications regarding such drug—]
(h)(2)(A)(i)(I)(I) [inserted: ]
(h)(2)(A)(i)(I)(aa)(aa) [inserted: ]
[inserted: that are made knowingly or recklessly; and]
(h)(2)(A)(i)(I)(bb)(bb) [inserted: ]
[inserted: contain a false or inaccurate statement or material omission of fact regarding a drug described in subparagraph (1); or]
(h)(2)(A)(i)(II)(II) [inserted: ]
[inserted: fail to include information in brief summary relating to side effects, contraindications, and effectiveness of the drug in the same manner and to the same extent as such information is required in prescription drug advertisements pursuant to section 502(n); and]
(h)(2)(A)(ii)(ii) [inserted: ]
[inserted: does not include—]
(h)(2)(A)(ii)(I)(I) [inserted: ]
[inserted: statements that take place in the course of bona fide patient care or medical research that are made by professionals engaged in such patient care or medical research; or]
(h)(2)(A)(ii)(II)(II) [inserted: ]
[inserted: statements that describe the person's own experience, opinion, or value judgment; and]
(h)(2)(B)(B) [inserted: ]
[inserted: the term “social media influencer” means a private individual who has perceived credibility or popularity and who expresses their opinions, beliefs, findings, recommendations, or experience on social media platforms to an audience, including in a manner conveying trust or expertise on a topic, for the purpose to promoting or advertising certain information or products or inducing behavior by the audience.]

21 U.S.C. § 352 Misbranded drugs and devices

+1 −1Shown
More for 21 U.S.C. § 352
Read § 352Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 502(n) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(n)) is amended by adding at the end the following: For purposes of this paragraph, manufacturer, packer, or distributor includes a person who issues or causes to be issued an advertisement or other descriptive printed matter with respect to a specific drug subject to section 503(b)(1) or compounded in accordance with section 503A or 503B, and who directly or indirectly offers to bring together a potential patient and a prescriber or dispenser through use of electronic information and telecommunication technologies to engage in prescribing or dispensing of any drug subject to section 503(b)(1). Nothing in this paragraph shall apply to a private communication between a practitioner licensed by law to prescribe or dispense a prescription drug (or an individual under the direct supervision of such a practitioner) and an individual patient or their representative..

§ 352(m)–(p)

Start of § 352 to (k) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(m)(m) Color additives; packing and labeling(m) Color additives; packing and labeling
If it is a color additive the intended use of which is for the purpose of coloring only, unless its packaging and labeling are in conformity with such packaging and labeling requirements applicable to such color additive, as may be contained in regulations issued under section 379e of this title.If it is a color additive the intended use of which is for the purpose of coloring only, unless its packaging and labeling are in conformity with such packaging and labeling requirements applicable to such color additive, as may be contained in regulations issued under section 379e of this title.
(n)(n) Prescription drug advertisements: established name; quantitative formula; side effects, contraindications, and effectiveness; prior approval; false advertising; labeling; construction of the Convention on Psychotropic Substances(n) Prescription drug advertisements: established name; quantitative formula; side effects, contraindications, and effectiveness; prior approval; false advertising; labeling; construction of the Convention on Psychotropic Substances
In the case of any prescription drug distributed or offered for sale in any State, unless the manufacturer, packer, or distributor thereof includes in all advertisements and other descriptive printed matter issued or caused to be issued by the manufacturer, packer, or distributor with respect to that drug a true statement of (1) the established name as defined in paragraph (e), printed prominently and in type at least half as large as that used for any trade or brand name thereof, (2) the formula showing quantitatively each ingredient of such drug to the extent required for labels under paragraph (e), and (3) such other information in brief summary relating to side effects, contraindications, and effectiveness as shall be required in regulations which shall be issued by the Secretary in accordance with section 371(a) of this title, and in the case of published direct-to-consumer advertisements the following statement printed in conspicuous text: “You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1–800-FDA-1088.”, except that (A) except in extraordinary circumstances, no regulation issued under this paragraph shall require prior approval by the Secretary of the content of any advertisement, and (B) no advertisement of a prescription drug, published after the effective date of regulations issued under this paragraph applicable to advertisements of prescription drugs, shall with respect to the matters specified in this paragraph or covered by such regulations, be subject to the provisions of sections 52 to 57 of title 15. This paragraph (n) shall not be applicable to any printed matter which the Secretary determines to be labeling as defined in section 321(m) of this title. Nothing in the Convention on Psychotropic Substances, signed at Vienna, Austria, on February 21, 1971, shall be construed to prevent drug price communications to consumers. In the case of an advertisement for a drug subject to section 353(b)(1) of this title presented directly to consumers in television or radio format and stating the name of the drug and its conditions of use, the major statement relating to side effects and contraindications shall be presented in a clear, conspicuous, and neutral manner.In the case of any prescription drug distributed or offered for sale in any State, unless the manufacturer, packer, or distributor thereof includes in all advertisements and other descriptive printed matter issued or caused to be issued by the manufacturer, packer, or distributor with respect to that drug a true statement of (1) the established name as defined in paragraph (e), printed prominently and in type at least half as large as that used for any trade or brand name thereof, (2) the formula showing quantitatively each ingredient of such drug to the extent required for labels under paragraph (e), and (3) such other information in brief summary relating to side effects, contraindications, and effectiveness as shall be required in regulations which shall be issued by the Secretary in accordance with section 371(a) of this title, and in the case of published direct-to-consumer advertisements the following statement printed in conspicuous text: “You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1–800-FDA-1088.”, except that (A) except in extraordinary circumstances, no regulation issued under this paragraph shall require prior approval by the Secretary of the content of any advertisement, and (B) no advertisement of a prescription drug, published after the effective date of regulations issued under this paragraph applicable to advertisements of prescription drugs, shall with respect to the matters specified in this paragraph or covered by such regulations, be subject to the provisions of sections 52 to 57 of title 15. This paragraph (n) shall not be applicable to any printed matter which the Secretary determines to be labeling as defined in section 321(m) of this title. Nothing in the Convention on Psychotropic Substances, signed at Vienna, Austria, on February 21, 1971, shall be construed to prevent drug price communications to consumers. In the case of an advertisement for a drug subject to section 353(b)(1) of this title presented directly to consumers in television or radio format and stating the name of the drug and its conditions of use, the major statement relating to side effects and contraindications shall be presented in a clear, conspicuous, and neutral manner.[inserted: For purposes of this paragraph, manufacturer, packer, or distributor includes a person who issues or causes to be issued an advertisement or other descriptive printed matter with respect to a specific drug subject to section 503(b)(1) or compounded in accordance with section 503A or 503B, and who directly or indirectly offers to bring together a potential patient and a prescriber or dispenser through use of electronic information and telecommunication technologies to engage in prescribing or dispensing of any drug subject to section 503(b)(1). Nothing in this paragraph shall apply to a private communication between a practitioner licensed by law to prescribe or dispense a prescription drug (or an individual under the direct supervision of such a practitioner) and an individual patient or their representative.]
(o)(o) Drugs or devices from nonregistered establishments(o) Drugs or devices from nonregistered establishments
If it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 360 of this title, if it is a drug and was imported or offered for import by a commercial importer of drugs not duly registered under section 381(s) of this title, if it was not included in a list required by section 360(j) of this title, if a notice or other information respecting it was not provided as required by such section or section 360(k) of this title, or if it does not bear such symbols from the uniform system for identification of devices prescribed under section 360(e) of this title as the Secretary by regulation requires.If it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 360 of this title, if it is a drug and was imported or offered for import by a commercial importer of drugs not duly registered under section 381(s) of this title, if it was not included in a list required by section 360(j) of this title, if a notice or other information respecting it was not provided as required by such section or section 360(k) of this title, or if it does not bear such symbols from the uniform system for identification of devices prescribed under section 360(e) of this title as the Secretary by regulation requires.
(p)(p) Packaging or labeling of drugs in violation of regulations(p) Packaging or labeling of drugs in violation of regulations
If it is a drug and its packaging or labeling is in violation of an applicable regulation issued pursuant to section 1472 or 1473 of title 15.If it is a drug and its packaging or labeling is in violation of an applicable regulation issued pursuant to section 1472 or 1473 of title 15.

Rest of § 352 unchanged

Step through the changes